In recent years, liquid biopsy has emerged as a groundbreaking approach in the field of oncology, offering a minimally invasive alternative to traditional tissue biopsies. This cutting-edge technology enables the detection of cancer-related biomarkers from bodily fluids such as blood, urine, and saliva, providing real-time insights into disease progression, treatment response, and genetic mutations. With advancements in research tools, services, and diagnostics, liquid biopsy is revolutionizing cancer care and precision medicine.
The global market for Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets is grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Liquid biopsy involves the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and other biomarkers present in bodily fluids. Unlike traditional biopsies, which require surgical intervention and may not always capture tumor heterogeneity, liquid biopsy offers a dynamic and comprehensive view of the disease at different time points.